Search

Your search keyword '"Martin Schuler"' showing total 253 results

Search Constraints

Start Over You searched for: Author "Martin Schuler" Remove constraint Author: "Martin Schuler" Topic medicine.disease Remove constraint Topic: medicine.disease
253 results on '"Martin Schuler"'

Search Results

1. HER2 mediates clinical resistance to the KRASG12C inhibitor sotorasib, which is overcome by co-targeting SHP2

2. Acquired Resistance to BRAF/MEK Inhibitor Therapy in BRAF-V600-mutated Squamous Cell Lung Cancer: Concurrent Evolvement of PTEN and MEK1 Mutations

3. Abstract PS10-31: Ribecca - a phase 3b, multi-center, open label study for women with estrogen receptor positive, locally advanced or metastatic breast cancer treated with ribociclib (lee011) in combination with letrozole: Final results

4. Impact of EBUS-TBNA in addition to [18F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC

5. Functional screening identifies aryl hydrocarbon receptor as suppressor of lung cancer metastasis

6. Abstract P1-19-31: RIBECCA - A phase IIIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole: Results of the third interim analysis

7. Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial

8. Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation

9. Combined multimodal ctDNA analysis and radiological imaging for tumor surveillance in Non-small cell lung cancer

10. 504 A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced stage solid tumors (Acronym: GDFATHER)

12. N-staging in large cell neuroendocrine carcinoma of the lung: diagnostic value of [18F]FDG PET/CT compared to the histopathology reference standard

13. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease

14. German Cancer Consortium (DKTK) – A national consortium for translational cancer research

15. Assessment of coronary artery disease during hospitalization for cancer treatment

16. BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy

17. GPR15 facilitates recruitment of regulatory T cells to promote colorectal cancer

18. Changes in fatigue, barriers, and predictors towards physical activity in advanced cancer patients over a period of 12 months : A comparative study

19. Combined systemic inflammation score (SIS) correlates with prognosis in patients with advanced pancreatic cancer receiving palliative chemotherapy

20. Sotorasib for Lung Cancers with KRAS p.G12C Mutation

21. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW) : a multi-cohort, open-label, registrational, phase 1/2 study

22. RAMucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic colorectal cancer : Safety results from the phase IIb part of the RAMTAS phase II/III trial of the German AIO (AIO-KRK-0316)

23. Antitumor immune response is associated with favorable survival in GEP-NEN G3

24. 247P Efficacy and safety of ribociclib (RIB) in combination with letrozole (LET) in patients with estrogen receptor–positive advanced breast cancer (ABC): Secondary and exploratory results of phase 3b RIBECCA study

25. Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

26. The impact of needle choice on molecular analysis of ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in NSCLC

27. Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesothelioma

28. Inhibiting fibroblast growth factor receptors in cancer - the next generation

29. Comparison of early tumour-associated versus late deaths in patients with central or7 cm T4 N0/1 M0 non-small-cell lung-cancer undergoing trimodal treatment: Only few risks left to improve

30. Improved survival in metastatic breast cancer: results from a 20-year study involving 1033 women treated at a single comprehensive cancer center

31. Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion : the impact of C-reactive protein and immune-checkpoint inhibition

32. Machine learning reveals a PD-L1–independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context

33. Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer : The CEBIFOX Trial

34. ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancer

35. ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy

36. Crizotinib in ROS1 and MET deregulated NSCLC-letter

37. Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols

38. 922P Efficacy of immunotherapy (IO) and subsequent systemic treatment after failure of IO in patients with recurrent or metastatic head and neck cancer in a real-world setting

39. Initial clinical experience with 90Y-FAPI-46 radioligand therapy for advanced stage solid tumors: a case series of nine patients

40. Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)

41. Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial

42. Deregulated BCL-2 family proteins impact on repair of DNA double-strand breaks and are targets to overcome radioresistance in lung cancer

43. A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer

44. High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer

45. 438P Interim safety analysis of the phase IIb study of ramucirumab in combination with TAS102 vs. TAS102 monotherapy in metastatic colorectal cancer: The RAMTAS trial of the German AIO

46. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study

47. Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer

48. Lymph Node Involvement and the Surgical Treatment of Thymic Epithelial and Neuroendocrine Carcinoma

49. Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules : analysis of the ESPATUE randomized phase 3 trial

50. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study

Catalog

Books, media, physical & digital resources